Prescriber beware: report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with contraindication
- 1 April 2015
- journal article
- Published by Elsevier BV in The American Journal of Emergency Medicine
- Vol. 33 (4), 604.e3-604.e4
- https://doi.org/10.1016/j.ajem.2014.09.039
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialThe Lancet, 2013
- The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Type 2 Diabetes MellitusPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Canagliflozin: First Global ApprovalDrugs, 2013